Guo Suyang, Yang Bo, Liu Hongli, Li Yuzhi, Li Shengze, Ma Ling, Liu Jian, Guo Wei
Department of Oncology Gynecology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China.
Department of Oncology Surgery, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233004, Anhui Province, China.
J Cancer Res Ther. 2017;13(4):689-692. doi: 10.4103/jcrt.JCRT_414_17.
The aim of this study was to evaluate the serum expression levels of squamous cell carcinoma antigen (SCC-Ag), highly sensitive C-reactive protein (hs-CRP), and CA-125 as potential serum biomarkers for recurrence of cervical cancer.
Eighty-six cervical cancer patients who received radical treatment were retrospectively included in this study from February 2011 to January 2014. Of the included 86 cases, 23 were recurred within the 36 months (recurrence group [RG]) and other 63 patients did not (non-RG [NRG]). The serum levels of SCC-Ag, hs-CRP, and CA-125 were examined and compared between the two groups. The prediction recurrence sensitivity, specificity area under the receiver operating characteristic curve were calculated by STATA11.0 software (http://www.stata.com). The correlation among SCC-Ag, hs-CRP, and CA-125 were analyzed by Pearson correlation test.
The serum levels of SCC-Ag, hs-CRP, and CA-125 were 1.29 (0.21-33.20) mg/mL, 4.78 (0.22-175.20) mg/mL, and 11.56 (2.028-123.66) IU/mL for NRG and 5.64 (0.50-136.80) mg/mL, 22.41 (0.56-588.90) mg/mL, and 25.41 (3.658-3687.00) IU/mL for RG, respectively. The serum levels of SCC-Ag, hs-CRP, and CA-125 in NG group were significant higher than those of NRG group (P < 0.05). The recurrence prediction sensitivity was 0.74, 0.65, and 0.74; specificity was 0.65, 0.63, and 0.58; area under the curve was 0.75, 0.66, and 0.67, respectively, for serum SCC-Ag, hs-CRP, and CA-125. Significant positive correlation between SCC-Ag and hs-CRP (rpearson = 0.20, P = 0.04), SCC-Ag and CA-125 (rpearson = 0.64, P < 0.001), hs-CRP and CA-125 (rpearson= -0.13, P = 0.56) was found in the RG patients.
Serum SCC-Ag, hs-CRP, and CA-125 were higher in recurrence cervical patients which could be potential biomarkers for predicting cervical cancer recurrence risk.
本研究旨在评估鳞状细胞癌抗原(SCC-Ag)、高敏C反应蛋白(hs-CRP)和CA-125的血清表达水平,作为宫颈癌复发的潜在血清生物标志物。
回顾性纳入2011年2月至2014年1月接受根治性治疗的86例宫颈癌患者。在纳入的86例患者中,23例在36个月内复发(复发组[RG]),其他63例患者未复发(非复发组[NRG])。检测并比较两组患者血清中SCC-Ag、hs-CRP和CA-125的水平。采用STATA11.0软件(http://www.stata.com)计算预测复发的敏感性、特异性及受试者工作特征曲线下面积。通过Pearson相关检验分析SCC-Ag、hs-CRP和CA-125之间的相关性。
非复发组血清SCC-Ag、hs-CRP和CA-125水平分别为1.29(0.21 - 33.20)mg/mL、4.78(0.22 - 175.20)mg/mL和11.56(2.028 - 123.66)IU/mL,复发组分别为5.64(0.50 - 136.80)mg/mL、22.41(0.56 - 588.90)mg/mL和25.41(3.658 - 3687.00)IU/mL。非复发组血清SCC-Ag、hs-CRP和CA-125水平显著高于复发组(P < 0.05)。血清SCC-Ag、hs-CRP和CA-125预测复发的敏感性分别为0.74、0.65和0.74;特异性分别为0.65、0.63和0.58;曲线下面积分别为0.75、0.66和0.67。复发组患者中,SCC-Ag与hs-CRP(rpearson = 0.20,P = 0.04)、SCC-Ag与CA-125(rpearson = 0.64,P < 0.001)、hs-CRP与CA-125(rpearson = -0.13,P = 0.56)之间存在显著正相关。
复发宫颈癌患者血清SCC-Ag、hs-CRP和CA-125水平较高,可能是预测宫颈癌复发风险的潜在生物标志物。